Resveratrol for inflammatory bowel disease in preclinical studies: a systematic review and meta-analysis

Yuting Gu, Yijie Lou, Zhanyi Zhou, Xuan Zhao, Xiaolu Ye, Shuwen Wu, Haitao Li, Yunxi JiFrontiers in Pharmacology 2024 · DOI

This systematic review and meta-analysis, published in Frontiers in Pharmacology, synthesizes preclinical evidence for using resveratrol—a natural polyphenol found in grapes and berries—to treat Inflammatory Bowel Disease (IBD). The study confirms that resveratrol significantly reduces intestinal damage and inflammation in animal models, particularly at doses exceeding 80 mg/kg, by modulating multiple signaling pathways and reducing oxidative stress.

TL;DR

Resveratrol shows robust therapeutic potential in animal models of IBD, significantly improving both clinical symptoms and underlying tissue pathology. Its efficacy is dose-dependent, with the most pronounced effects seen at dosages above 80 mg/kg, driven by its ability to suppress pro-inflammatory cytokines and boost antioxidant defenses.

What Problem Does This Paper Address?

Inflammatory Bowel Disease (IBD), including Ulcerative Colitis and Crohn’s Disease, is a chronic, relapsing condition characterized by out-of-control intestinal inflammation. While current treatments like 5-aminosalicylates (5-ASA) and biologics exist, they often come with significant side effects, high costs, or diminishing efficacy over time due to drug resistance.

There is a growing interest in "nutraceuticals"—compounds derived from food—as adjunctive therapies. Resveratrol (RSV) has long been touted for its antioxidant properties, but individual animal studies have shown varying results. This paper addresses the need for a rigorous, quantitative synthesis of these preclinical studies to determine if RSV is truly effective, what the optimal dose might be, and which biological mechanisms are actually at play.

Methods

The authors conducted a systematic review and meta-analysis following PRISMA guidelines.

  • Search Strategy: They queried major databases (PubMed, Embase, Web of Science, and several Chinese databases) for studies up to September 2023.
  • Quality Assessment: To ensure the reliability of the animal data, they used the CAMARADES 10-point quality checklist, which looks for features like peer-reviewed publication, random allocation, and blinded outcome assessment.
  • Statistical Analysis: They utilized Review Manager 5.4 to calculate Weighted Mean Differences (WMD) for primary outcomes (like the histopathological index) and Standardized Mean Differences (SMD) for biochemical markers.
  • Subgroup Analysis: The researchers broke down the data by animal species, sex, IBD modeling method (e.g., DSS vs. TNBS), and RSV dosage to find specific trends.

Datasets

The study did not generate a new experimental dataset but rather aggregated data from 28 preclinical studies involving:

  • Species: 23 studies in mice and 5 in rats.
  • Models: Primarily Dextran Sulfate Sodium (DSS)-induced colitis (22 studies), followed by TNBS (5) and Oxazolone (1).
  • Comparisons: All included studies compared a resveratrol-treated group against a model control group.

Key Insights and Ideas

  • The "High-Dose" Advantage: The meta-analysis revealed a clear dose-response relationship. While RSV was effective across the board, doses >80 mg/kg provided significantly better protection against tissue damage (WMD = -3.47) compared to lower doses.
  • Tissue Repair vs. Symptom Management: RSV didn't just mask symptoms (like diarrhea or weight loss); it significantly lowered the histopathological index (HI). This means it helped preserve the physical architecture of the intestinal mucosa and reduced the infiltration of inflammatory cells.
  • Multi-Target Mechanism: RSV doesn't just hit one pathway. The authors identified a "web" of mechanisms (see Figure 3 in the paper):
  • Anti-inflammatory: It inhibits the NF-κB and PI3K/Akt pathways while activating SIRT1.
  • Antioxidant: It reduces Malondialdehyde (MDA) and Myeloperoxidase (MPO) while boosting Superoxide Dismutase (SOD).
  • Microbiota Modulation: Several studies suggested RSV helps restore gut microbial diversity (e.g., increasing Akkermansia).
  • Bioavailability and Vehicle: Interestingly, RSV dissolved in saline or CMC (carboxymethylcellulose) showed higher efficacy than when it was simply mixed into standard lab chow, likely due to better stability and absorption.

Key Results

  • Histopathological Index: RSV treatment led to a significant reduction in tissue damage (WMD = -2.58, p < 0.00001).
  • Disease Activity Index (DAI): Clinical symptoms were significantly alleviated (WMD = -1.75).
  • Physical Indicators: RSV-treated animals showed a 10.33% improvement in body weight and significantly longer colons (a proxy for reduced inflammation/scarring) compared to controls.
  • Cytokine Profile: There was a massive reduction in pro-inflammatory markers:
  • TNF-α: SMD = -2.85
    • IL-6: SMD = -5.15
    • IL-1β: SMD = -3.38
    • IL-10 (Anti-inflammatory): Significantly increased (SMD = 3.51).

Limitations and Future Work

  • The "Translation Gap": Animal models of IBD are usually acute (7–14 days), whereas human IBD is a decades-long chronic condition. The rapid modeling cycle in animals may overstate the "cure" potential.
  • Bioavailability: Resveratrol is notorious for poor bioavailability in humans. The authors suggest that future clinical applications may require nano-formulations or specific delivery systems (like CMC) to be effective.
  • Sex Bias: Most included studies used male animals. Given that IBD affects all genders, more research on female animal models is necessary to understand potential hormonal interactions.
  • Publication Bias: The funnel plots showed some asymmetry, suggesting that studies with negative results might be under-reported in the literature.

Summary updated

Abstract

<b>Background:</b> Inflammatory bowel disease (IBD) is a chronic condition that can be managed with treatment, but it is challenging to get IBD cured. Resveratrol, a non-flavonoid polyphenolic organic compound derived from various plants, has a potential effect on IBD. The current research was set out to investigate the therapeutic effects of resveratrol on animal models of IBD. <b>Methods:</b> A comprehensive search of PubMed, Embase, Web of Science, and Chinese databases was performed. The literature search process was completed independently by two people and reviewed by a third person. The risk of bias in the included literature was assessed using the Collaborative Approach to Meta Analysis and Review of Animal Data from Experimental Stroke (CAMARADES) 10-point quality checklist. The meta-analysis utilized Review Manager 5.4 software to evaluate the efficacy of resveratrol, with histopathological index as the primary outcome measure. Subgroup analysis was conducted based on this indicator. Additionally, meta-analyses were carried out on different outcomes reported in the literature, including final disease activity index, final body weight change, colon length, splenic index, and inflammatory factors. <b>Results:</b> After conducting a thorough literature search and selection process, a total of 28 studies were ultimately included in the analysis. It was found that over half of the selected studies had more than five items with low risk of bias in the bias risk assessment. Relevant datas from included literature indicated that the histopathological index of the resveratrol group was significantly lower than that of the control group (WMD = -2.58 [-3.29, -1.87]). Subgroup analysis revealed that higher doses of resveratrol (>80 mg/kg) had a better efficacy (WMD = -3.47 [-4.97, -1.98]). Furthermore, The data summary and quantitative analysis results of SI and colon length also showed that resveratrol was effective in alleviating intestinal mucosal pathological injury of IBD. In terms of biochemical indicators, the summary analysis revealed that resveratrol affected interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α), transforming growth factor-β (TGF-β), interferon-γ (IFN-γ), malondialdehyde (MDA), myeloperoxidase (MPO), superoxide dismutase (SOD), and prostaglandin E2 (PGE2) significantly. These effects may be attributed to the mechanism of resveratrol in regulating immune response and inhibiting oxidative stress. <b>Conclusion:</b> This review suggests that resveratrol demonstrated a notable therapeutic impact in preclinical models of IBD, particularly at doses exceeding 80 mg/kg. This efficacy is attributed to the protective mechanisms targeting the intestinal mucosa involved in the pathogenesis of IBD through various pathways. As a result, resveratrol holds promising prospects for potential clinical use in the future.
BibTeX
@inproceedings{gu2024resveratrol,
  author = {Yuting Gu and Yijie Lou and Zhanyi Zhou and Xuan Zhao and Xiaolu Ye and Shuwen Wu and Haitao Li and Yunxi Ji},
  title = {{Resveratrol for inflammatory bowel disease in preclinical studies: a systematic review and meta-analysis}},
  booktitle = {Frontiers in Pharmacology},
  year = {2024},
  doi = {10.3389/fphar.2024.1411566},
}
Figure